Author

Tom Kouroukis

Observed names: T Kouroukis, T. Kouroukis, T.C. Kouroukis, Tom C. Kouroukis

Institutions: Cancer Care Ontario, Ontario Health, Hamilton Health Sciences, McMaster University

Observed institutions: Cancer Care Ontario, Juravinski Cancer Centre, Queen Elizabeth II Health Sciences Centre, Juravinski Hospital, Princess Margaret Cancer Centre, Eastern Cooperative Oncology Group, National Cancer Institute, Ontario Health, Saskatoon Cancer Centre, St. Joseph’s Healthcare Hamilton, Hamilton Health Sciences, McMaster University

OpenAlex ID: A5108315329

Bortezomib in Multiple Myeloma: Systematic Review and Clinical Considerations

2014 · T.C. Kouroukis, F.G. Baldassarre, et al. · Current Oncology · 127

PDF

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group

2016 · Matthew D. Seftel, John Kuruvilla, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 47

A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191

2015 · Annette E. Hay, Alli Murugesan, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 38

PML/RARα APL with undifferentiated morphology and stem cell immunophenotype

1998 · R Foley, P Soamboonsrup, et al. · Leukemia · 20

Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline

2016 · A. Prica, F. Baldassarre, et al. · Clinical Oncology · 19

Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

2016 · Nizar J. Bahlis, Rami Kotb, et al. · Blood · 16

Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

2016 · Christine Chen, Rami Kotb, et al. · Blood · 11

Are Oral Bisphosphonates Effective in Improving Lumbar Bone Mineral Density in Breast Cancer Survivors With Osteopenia or Osteoporosis?

2005 · Anna M. Sawka, George Ioannidis, et al. · Journal of Obstetrics and Gynaecology Canada · 8

An Evaluation of Age-related Differences in Quality of Life Preferences in Patients with Non-Hodgkin's Lymphoma

2004 · Tom Kouroukis, Ralph Meyer, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 8

Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study

2024 · Alissa Visram, Kelvin Kar-Wing Chan, et al. · Haematologica · 5

PDF

Bortezomib is active in Waldenstrom’s Macroglobulinemia (WM)—Results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM

2006 · C. I. Chen, T. Kouroukis, et al. · Journal of Clinical Oncology · 5

First-Line Therapy, Autologous Stem-Cell Transplantation, and Post-Transplantation Maintenance in the Management of Newly Diagnosed Mantle Cell Lymphoma

2020 · S. Bhella, Norma Varela, et al. · Current Oncology · 3

PDF

Cost-Utility Of Bortezomib In Induction Treatment Prior To Autologous Stem-Cell Transplantation (ASCT) In Previously Untreated Multiple Myeloma Patients In Canada

2013 · Tom Kouroukis, Darrell White, et al. · Blood · 3

Secondary Malignancies Following CAR T‐Cell Therapy for B‐Cell Malignancies: A Retrospective Analysis

2025 · Joanne Britto, Audrey Y. H. Dong, et al. · eJHaem · 2

PDF

Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy

2024 · Amaris Balitsky, GR Pond, et al. · BMC Cancer · 2

PDF

Approach to Fever Assessment in Ambulatory Cancer Patients Receiving Chemotherapy: A Clinical Practice Guideline

2016 · M.K. Krzyzanowska, C. Walker-Dilks, et al. · Current Oncology · 2

PDF

Developing Organizational Requirements to Standardize Delivery and Improve Quality of Acute Leukemia Care in Ontario

2024 · Leslie Verville, Cassandra McKay, et al. · Current Oncology · 1

PDF

A structured oral chemotherapy teaching tool to improve adherence in adults with multiple myeloma: A pilot randomized controlled trial

2024 · Imran Haider, Gregory R. Pond, et al. · Journal of Geriatric Oncology · 1

AML-303: Systematic Review of Frailty Assessment Tools for Elderly Patients with Acute Myeloid Leukemia

2020 · Dina Khalaf, Tobias Berg, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Rituximab in Lymphoma and Chronic Lymphocytic Leukemia: A Clinical Practice Guideline, Version 3

2015 · Anca Prica, Fulvia Baldassarre, et al. · 1

A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND.191

2014 · Annette E Hay, Alli Murugesan, et al. · Blood · 1

Comparative effectiveness of chimeric antigen receptor (CAR) T‐cell therapy versus historical controls in patients with relapse/refractory aggressive B‐cell lymphoma: An indirect treatment comparison in the real‐world setting

2026 · Pierre J. A. Villeneuve, Lee Mozessohn, et al. · British Journal of Haematology

A Prospective Population-Based Study of Chimeric Antigen Receptor T-Cell Therapy for Patients with Diffuse Large B-Cell Lymphoma

2026 · Lee Mozessohn, Pierre J. A. Villeneuve, et al. · Current Oncology

PDF

The impact of distance to CAR-T centre on CAR-T delivery and CAR-T outcomes: A single centre retrospective cohort study

2025 · Bradley Rutherford, Gregory Pond, et al. · Blood

PDF

Patterns of palliative care utilization across health sectors in patients with aggressive non-Hodgkin lymphoma.

2025 · Joanne Britto, Ana Gayowsky, et al. · Blood

Works count: 36

Citation count: 321

H-index: 8

I10-index: 7